Trials / Completed
CompletedNCT03410992
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 435 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Bimekizumab will be provided at pre-specified time intervals. |
| OTHER | Placebo | Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products. |
Timeline
- Start date
- 2018-02-05
- Primary completion
- 2018-12-28
- Completion
- 2020-01-07
- First posted
- 2018-01-25
- Last updated
- 2026-04-15
- Results posted
- 2022-03-04
Locations
77 sites across 9 countries: United States, Australia, Canada, Germany, Hungary, Poland, Russia, South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03410992. Inclusion in this directory is not an endorsement.